Dermatopontin Double Nickase Plasmid (h): sc-402924-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Dermatopontin Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Dermatopontin Double Nickase Plasmid (h) and Dermatopontin Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DPT. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Dermatopontin Antibody (F-4): sc-376863
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dermatopontin Double Nickase Plasmid (h) | sc-402924-NIC | 20 µg | $410.00 | |||
Dermatopontin Double Nickase Plasmid (h2) | sc-402924-NIC-2 | 20 µg | $410.00 |
Human DPT encodes dermatopontin, an extracellular matrix protein enriched in connective tissues that modulates collagen fibrillogenesis, matrix assembly, and cell–matrix adhesion. Dermatopontin influences signaling crosstalk between the extracellular matrix and cells, impacting processes such as wound repair, fibroblast activity, and tissue remodeling through interactions with matrix components and growth factor pathways. Altered DPT expression has been associated with fibrosis-related remodeling and tumor microenvironment changes where extracellular matrix organization and stiffness can affect cell behavior. As a matrix regulator, DPT is frequently studied in mechanisms governing stromal biology, angiogenesis, and inflammatory responses linked to extracellular matrix turnover.
Dermatopontin Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DPT locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DPT. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DPT function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DPT-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.